PMID- 30630986 OWN - NLM STAT- MEDLINE DCOM- 20200616 LR - 20200616 IS - 1592-8721 (Electronic) IS - 0390-6078 (Print) IS - 0390-6078 (Linking) VI - 104 IP - 8 DP - 2019 Aug TI - Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. PG - 1626-1632 LID - 10.3324/haematol.2018.205567 [doi] AB - Attenuated human leukocyte antigen (HLA) class I expression is implicated as a major immune escape mechanism in several types of tumor. We previously reported that HLA class I/beta2 microglobulin and programmed death ligand-1 expression are prognostic factors in adult T-cell leukemia/lymphoma. A recent report suggested that HLA class II expression is also an important prognostic factor for the clinical outcome of programmed death-1 blockade therapy in recurrent/refractory Hodgkin lymphoma. This prompted us to evaluate HLA class II expression in adult T-cell leukemia/lymphoma and to compare the findings with the patients' clinicopathological features. Of the 132 biopsy specimens examined from newly diagnosed patients, lymphoma cells were positive for HLA class II expression in 44 patients (33.3%), whereas programmed death ligand-1 expression was observed on neoplastic cells from nine patients (6.9%) and on stromal cells in the tumor microenvironment in 83 cases (62.9%). HLA class II-positive cases showed a significantly better overall survival compared to the HLA class II-negative cases (P<0.0001). Patients positive for HLA class II and programmed death ligand-1 microenvironmental expression had significantly better prognosis than the other groups (P<0.0001). HLA class II-positive and HLA class II-negative groups also showed a significant difference in complete remission rate (P=0.0421), HLA class I/beta2 microglobulin expression (P=0.0165), and the number of programmed death-1-positive tumor infiltrating cells (P=0.0020). HLA class II expression was a prognostic factor for overall survival both in univariate and multivariate analyses (P<0.0001 and P=0.0007, respectively). Our study reveals that HLA class II is a novel prognostic factor in adult T-cell leukemia/lymphoma. CI - Copyright(c) 2019 Ferrata Storti Foundation. FAU - Takeuchi, Mai AU - Takeuchi M AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Miyoshi, Hiroaki AU - Miyoshi H AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Asano, Naoko AU - Asano N AD - Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka, Nagano. FAU - Yoshida, Noriaki AU - Yoshida N AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. AD - Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan. FAU - Yamada, Kyohei AU - Yamada K AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Yanagida, Eriko AU - Yanagida E AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Moritsubo, Mayuko AU - Moritsubo M AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Nakata, Michiko AU - Nakata M AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Umeno, Takeshi AU - Umeno T AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Suzuki, Takaharu AU - Suzuki T AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Komaki, Satoru AU - Komaki S AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Muta, Hiroko AU - Muta H AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Furuta, Takuya AU - Furuta T AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Seto, Masao AU - Seto M AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka. FAU - Ohshima, Koichi AU - Ohshima K AD - Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka ohshima_kouichi@med.kurume-u.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190110 PL - Italy TA - Haematologica JT - Haematologica JID - 0417435 RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) RN - 0 (Histocompatibility Antigens Class II) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - B7-H1 Antigen/genetics/metabolism MH - Biomarkers MH - Biomarkers, Tumor/metabolism MH - Combined Modality Therapy MH - Female MH - *Gene Expression MH - Histocompatibility Antigens Class II/*genetics MH - Humans MH - Immunohistochemistry MH - Leukemia-Lymphoma, Adult T-Cell/*genetics/*mortality/pathology/therapy MH - Male MH - Middle Aged MH - Prognosis PMC - PMC6669171 EDAT- 2019/01/12 06:00 MHDA- 2020/06/17 06:00 PMCR- 2019/08/01 CRDT- 2019/01/12 06:00 PHST- 2018/08/28 00:00 [received] PHST- 2019/01/09 00:00 [accepted] PHST- 2019/01/12 06:00 [pubmed] PHST- 2020/06/17 06:00 [medline] PHST- 2019/01/12 06:00 [entrez] PHST- 2019/08/01 00:00 [pmc-release] AID - haematol.2018.205567 [pii] AID - 1041626 [pii] AID - 10.3324/haematol.2018.205567 [doi] PST - ppublish SO - Haematologica. 2019 Aug;104(8):1626-1632. doi: 10.3324/haematol.2018.205567. Epub 2019 Jan 10.